Abstract CD56 antigen, a 200–220 kDa cell surface glycoprotein, identified as an isoform of
the neural adhesion molecules (NCAM), has been found frequently expressed in several …

BACKGROUND AND OBJECTIVES. CD56 antigen expression has been reported in several
hematologic malignancies. In acute myeloid leukemia (AML) M2 with t (8; 21) and acute …

BACKGROUND: The expression of CD56 is considered a bad prognostic factor for overall
survival, lower rates or short complete remission and extramedullary invasion but the results …

The CD56 antigen is normally expressed on natural-killer cells but has additionally been
shown to be present on a variety of hematologic malignancies, including a subset of acute …

Bone marrow and peripheral blood samples from 36 patients with Philadelphia chromosome
positive chronic myelogenous leukemia (Ph+ CML)(30 in chronic phase, four in accelerated …

BACKGROUND AND OBJECTIVES: Overexpression of P-glycoprotein (PGP), a multidrug-
related (MDR) protein, is one of the most important factors responsible for reduced drug …

CD56 expression in acute myeloid leukemia (AML) has been associated with
extramedullary leukemia and multidrug resistance, but its clinical and prognostic …

The mechanisms of extramedullary leukemic infiltration are not well characterized. The cell-
surface glycoprotein CD56, which is identical to the neural cell adhesion molecule, may be …

Although acute myeloid leukemia (AML) with t (8; 21)(q22; q22) is associated with a high
complete remission (CR) rate and prolonged disease-free survival, treatment outcome is not …

Adhesion molecules CD58 and CD54 are involved in cell-cell interactions that are
potentially important in the biology of acute leukemia (AL). Expression of these molecules …